Prexige, Pulled In Australia, Still Viable: Novartis

Law360, New York (August 14, 2007, 12:00 AM EDT) -- Novartis AG has continued to insist that its painkiller Prexige is a viable option for some patients, after the drug was yanked from the Australian market and authorities there urged patients to stop taking it based on reports linking the drug to severe liver damage, allegedly resulting in two deaths and two liver transplants.

Tuesday, Novartis spokesman John Gilardi said that the company still believed that Prexige, which is the brand name for lumiracoxib, should remain an option for doctors and certain patients managing acute pain....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.